Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study

Table 2 Univariate and multivariate analyses of the prognostic factors of OS in AGC patients with SPM (n = 129)

Variables	Univariate analysis			Multivariate analysis
Variables	HR	[95% CI]	p-value	HR	[95% CI]	p-value
Regimen
FP (vs. F)	0.56	[0.39–0.82]	< 0.01	0.47	[0.31–0.72]	< 0.01
Age
≥65 (vs. < 65)	0.80	[0.55–1.17]	0.25
Sex
Female (vs. male)	1.05	[0.72–1.54]	0.78
PS
2–4 (vs. 0–1)	1.22	[0.83–1.79]	0.32	0.95	[0.62–1.48]	0.83
Histology
Intestinal (vs. diffuse)	0.71	[0.43–1.19]	0.19	0.70	[0.41–1.19]	0.18
Unknown (vs. diffuse)	NA		NA	NA		NA
Disease status
Recurrent (vs. advanced)	0.58	[0.25–1.32]	0.19	0.86	[0.36–2.10]	0.75
Primary site
GEJ (vs. stomach)	0.98	[0.40–2.41]	0.96
No. of metastatic sites
≥3 (vs. 1–2)	1.43	[0.92–2.23]	0.11	1.64	[0.97–2.76]	0.07
Target lesion
Absence (vs. presence)	0.95	[0.65–1.38]	0.78
Subtype of SPM
Inadequate oral intake (vs. massive ascites)	0.81	[0.52–1.29]	0.38	0.58	[0.33–1.00]	0.05
Both (vs. massive ascites)	1.09	[0.69–1.71]	0.71	0.76	[0.44–1.29]	0.31
Serum albumin level
< 3.1 g/ml (vs. > 3.1 g/ml)	1.42	[0.97–2.07]	0.07	1.43	[0.94–2.17]	0.09

AGC advanced gastric cancer, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, GEJ gastroesophageal junction, HR hazard ratio, NA not assessed, OS overall survival, SPM severe peritoneal metastasis